Skip to main content
Erschienen in: Annals of Hematology 10/2013

01.10.2013 | Original Article

Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin’s lymphoma

verfasst von: Ahmed M. L. Bedewy, Maha M. Adel Elgammal, Magdy M. L. Bedewy, Shereen M. EL-Maghraby

Erschienen in: Annals of Hematology | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

The soluble decoy receptor 3 (DcR3) is a member of the tumor necrosis factor receptor superfamily whose overexpression has been observed in several human malignancies. Survivin is one of the inhibitors of apoptosis proteins that are thought to play an important role in the pathogenesis of malignancies. We aimed to evaluate the expression of DcR3 in relation to survivin in B cell non-Hodgkin`s lymphoma (NHL) and then we focused on patients with diffuse large B cell non-Hodgkin’s lymphoma (DLBCL) (50 cases) and correlated DcR3 expression with survivin expression and other prognostic parameters. Fifteen subjects with reactive lymphoid hyperplasia were included as controls. The expression of DcR3 and survivin were analyzed by immunohistochemistry on formalin-fixed paraffin-embedded lymph node sections from 80 cases of B cell NHL and 15 controls. Bone marrow biopsy sections of patients were also immunostained with the previous markers. Results: DcR3 expression was found in 32.5 % of B cell NHL patients versus 6.7 % of controls (p <0.001) and was associated with the aggressive/highly aggressive subtypes. DcR3 was strongly expressed in 30 % of DLBCL patients, where it was associated with survivin expression, high international prognostic index (IPI), the presence of extra nodal disease, ECOG performance status >1, reduced remission rates and shorter event-free survival. The expression of survivin was 40 % in B cell NHL patients versus 13.3 % in the control group (p <0.001). The expression of survivin in aggressive/highly aggressive B cell NHL was significantly higher than that in indolent B cell NHL. Survivin expression has been detected in 44 % of the DLBCL patients and was associated with their clinical stage and shorter event-free survival (p = 0.026). Bone marrow biopsy sections from DLBCL patients showed significant DcR3 and survivin over expressions in sections with infiltration by lymphoma cells than sections with no infiltration. Conclusion: DcR3 expression was associated with other prognostic factors including survivin, reduced remission rates, and shorter event-free survival. Survivin is closely related to aggressive/highly aggressive subtypes of B cell NHL and is associated with shorter event-free survival. Both DcR3 and survivin expressions on bone marrow sections can be of help in diagnosing bone marrow infiltration.
Literatur
1.
Zurück zum Zitat Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morlé A, Iessi E, Morizot A, Garrido C, Guillaudeux T, Micheau O (2012) Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin’s lymphoma B cells. Haematologica 97(1):38–46. doi:10.3324/haematol.2011.046466, Epub 2011 Sep 20PubMedCrossRef Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morlé A, Iessi E, Morizot A, Garrido C, Guillaudeux T, Micheau O (2012) Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin’s lymphoma B cells. Haematologica 97(1):38–46. doi:10.​3324/​haematol.​2011.​046466, Epub 2011 Sep 20PubMedCrossRef
2.
Zurück zum Zitat Tilly H, Dreyling M (2010) Diffuse large B cell non-Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(5):172–174CrossRef Tilly H, Dreyling M (2010) Diffuse large B cell non-Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(5):172–174CrossRef
3.
Zurück zum Zitat Kumar V, Abbas AK, Fausto N, Aster JC (2009) Robbins and Cotran pathologic basis of disease. Elsevier Health Sciences Kumar V, Abbas AK, Fausto N, Aster JC (2009) Robbins and Cotran pathologic basis of disease. Elsevier Health Sciences
4.
Zurück zum Zitat Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328(14):1002–1006PubMedCrossRef Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328(14):1002–1006PubMedCrossRef
5.
Zurück zum Zitat Groves FD, Linet MA, Travis LB, Devesa SS (2000) Cancer surveillance series: non-Hodgkin’s lymphoma: incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 19:1240–1251CrossRef Groves FD, Linet MA, Travis LB, Devesa SS (2000) Cancer surveillance series: non-Hodgkin’s lymphoma: incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 19:1240–1251CrossRef
6.
Zurück zum Zitat Bartl R, Frisch B, Burkhardt R et al (1984) Lymphoproliferations in the bone marrow: identification and evolution; classification and staging. J Clin Pathol 37:233–254PubMedCrossRef Bartl R, Frisch B, Burkhardt R et al (1984) Lymphoproliferations in the bone marrow: identification and evolution; classification and staging. J Clin Pathol 37:233–254PubMedCrossRef
7.
Zurück zum Zitat Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S (2006) The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 76(6):473–480PubMedCrossRef Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S (2006) The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 76(6):473–480PubMedCrossRef
8.
Zurück zum Zitat Pitti RM, Marsters SA, Lawrence DA et al (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699–703PubMedCrossRef Pitti RM, Marsters SA, Lawrence DA et al (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699–703PubMedCrossRef
9.
Zurück zum Zitat Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell co-stimulator. Immunity 16:479–492PubMedCrossRef Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell co-stimulator. Immunity 16:479–492PubMedCrossRef
10.
Zurück zum Zitat Ge Z, Sanders AJ, Ye L, Jiang WG (2011) Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer. Exp Ther Med 2(2):167–172PubMed Ge Z, Sanders AJ, Ye L, Jiang WG (2011) Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer. Exp Ther Med 2(2):167–172PubMed
11.
Zurück zum Zitat Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, Hsieh SL (2005) Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol 175:5135–5145PubMed Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, Hsieh SL (2005) Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol 175:5135–5145PubMed
12.
Zurück zum Zitat Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W (2008) Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 10:1049–1056PubMed Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W (2008) Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 10:1049–1056PubMed
13.
Zurück zum Zitat Takahama Y, Yamada Y, Emoto K et al (2002) The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5:61–68PubMedCrossRef Takahama Y, Yamada Y, Emoto K et al (2002) The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5:61–68PubMedCrossRef
14.
Zurück zum Zitat Guha M, Altieri DC (2009) Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8:2708–2710PubMedCrossRef Guha M, Altieri DC (2009) Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8:2708–2710PubMedCrossRef
15.
Zurück zum Zitat Li F, Yang J, Ramnath N et al (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509–512PubMedCrossRef Li F, Yang J, Ramnath N et al (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509–512PubMedCrossRef
16.
Zurück zum Zitat Harfouche R, Hassessian HM, Guo Y et al (2002) Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 64:135–147PubMedCrossRef Harfouche R, Hassessian HM, Guo Y et al (2002) Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 64:135–147PubMedCrossRef
17.
Zurück zum Zitat Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22:1682–1688PubMedCrossRef Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22:1682–1688PubMedCrossRef
18.
Zurück zum Zitat Dohi T, Okada K, Xia F et al (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279:34087–34090PubMedCrossRef Dohi T, Okada K, Xia F et al (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279:34087–34090PubMedCrossRef
19.
Zurück zum Zitat Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 8:917–921CrossRef Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 8:917–921CrossRef
20.
Zurück zum Zitat Siegel S, Wagner A, Schmitz N, Zeis M (2003) Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 122:911–914PubMedCrossRef Siegel S, Wagner A, Schmitz N, Zeis M (2003) Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 122:911–914PubMedCrossRef
21.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef
22.
Zurück zum Zitat Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Costwolds meeting. J Clin Oncol 7(11):1630–1636PubMed Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Costwolds meeting. J Clin Oncol 7(11):1630–1636PubMed
23.
Zurück zum Zitat The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994CrossRef The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994CrossRef
24.
Zurück zum Zitat Kate C, Anthony HG (2010) Non-Hodgkin lymphoma. Postgraduate Hematology,sixth edition, by Blackwell Publishing 655–685 Kate C, Anthony HG (2010) Non-Hodgkin lymphoma. Postgraduate Hematology,sixth edition, by Blackwell Publishing 655–685
25.
Zurück zum Zitat Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working group. J Clin Oncol 17:1244–1253PubMed Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working group. J Clin Oncol 17:1244–1253PubMed
26.
Zurück zum Zitat Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, Wang WS, Yen CC, Gau JP, Yang MH (2008) Expression of a soluble decoy receptor 3 in patients with diffuse large B cell lymphoma predicts clinical outcome. Int J Oncol 33(3):549–554PubMed Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, Wang WS, Yen CC, Gau JP, Yang MH (2008) Expression of a soluble decoy receptor 3 in patients with diffuse large B cell lymphoma predicts clinical outcome. Int J Oncol 33(3):549–554PubMed
27.
Zurück zum Zitat Aktaş S, Kargi A, Olgun N, Diniz G, Erbay A, Vergin C (2009) Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein–Barr virus positive and negative pediatric non-Hodgkin’s lymphoma. Pathol Oncol Res 15(3):345–350PubMedCrossRef Aktaş S, Kargi A, Olgun N, Diniz G, Erbay A, Vergin C (2009) Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein–Barr virus positive and negative pediatric non-Hodgkin’s lymphoma. Pathol Oncol Res 15(3):345–350PubMedCrossRef
28.
Zurück zum Zitat Watanuki-Miyauchi R, Kojima Y, Tsurumi H, Hara T, Goto N, Kasahara S, Saio M, Moriwaki H, Takami T (2005) Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B cell lymphoma and its subtypes. Pathol Int 55(6):324–330PubMedCrossRef Watanuki-Miyauchi R, Kojima Y, Tsurumi H, Hara T, Goto N, Kasahara S, Saio M, Moriwaki H, Takami T (2005) Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B cell lymphoma and its subtypes. Pathol Int 55(6):324–330PubMedCrossRef
29.
Zurück zum Zitat Arber DA, George TI (2005) Bone marrow biopsy involvement by non-Hodgkin’s lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol 29(12):1549–1557PubMedCrossRef Arber DA, George TI (2005) Bone marrow biopsy involvement by non-Hodgkin’s lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol 29(12):1549–1557PubMedCrossRef
30.
Zurück zum Zitat Liang Q, Wang B, Li G (2009) DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B 10(9):675–682PubMedCrossRef Liang Q, Wang B, Li G (2009) DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B 10(9):675–682PubMedCrossRef
31.
Zurück zum Zitat Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U (2008) Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas. Leuk Res 32(2):243–50 Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U (2008) Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas. Leuk Res 32(2):243–50
32.
Zurück zum Zitat Zuo XL, Zhou X, Meng J, Zhang KJ, Liu XH, Yang HQ (2006) A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin’s lymphoma. Zhonghua Nei Ke Za Zhi 45(2):133–135PubMed Zuo XL, Zhou X, Meng J, Zhang KJ, Liu XH, Yang HQ (2006) A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin’s lymphoma. Zhonghua Nei Ke Za Zhi 45(2):133–135PubMed
33.
Zurück zum Zitat Gu X, Lin HL (2004) Analysis of survivin expression in subtypes of lymphoma. Ai Zheng 23(6):655–661PubMed Gu X, Lin HL (2004) Analysis of survivin expression in subtypes of lymphoma. Ai Zheng 23(6):655–661PubMed
34.
Zurück zum Zitat Lin L, Min Z, Ping Z (2007) Expression of PLK1 and survivin in diffuse large B cell lymphoma. Leuk Lymphoma 48:2179–2183CrossRef Lin L, Min Z, Ping Z (2007) Expression of PLK1 and survivin in diffuse large B cell lymphoma. Leuk Lymphoma 48:2179–2183CrossRef
35.
Zurück zum Zitat Li J, Wu H (2006) Expression of survivin in human non-Hodgkin lymphoma and its correlation with proliferation and angiogenesis. J Huazhong Univ Sci Technolog Med Sci 26(5):504–507PubMedCrossRef Li J, Wu H (2006) Expression of survivin in human non-Hodgkin lymphoma and its correlation with proliferation and angiogenesis. J Huazhong Univ Sci Technolog Med Sci 26(5):504–507PubMedCrossRef
36.
Zurück zum Zitat Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Martinovic T, Filipovic B, Stanisavljevic D, Zivković R, Hajder J, Stanisavljevic N, Mihaljevic B (2012) Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). Med Oncol 29(5):3515–3521PubMedCrossRef Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Martinovic T, Filipovic B, Stanisavljevic D, Zivković R, Hajder J, Stanisavljevic N, Mihaljevic B (2012) Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). Med Oncol 29(5):3515–3521PubMedCrossRef
37.
Zurück zum Zitat Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H et al (2000) Prognostic significance of survivin expression in diffuse large B cell lymphomas. Blood 96(5):1921–1925PubMed Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H et al (2000) Prognostic significance of survivin expression in diffuse large B cell lymphomas. Blood 96(5):1921–1925PubMed
38.
Zurück zum Zitat Sung J, Lim S, Kim Y, Lee J (2010) Prognostic significance of pSTAT3 and survivin expression in diffuse large B cell lymphoma. Basic and Appl Pathol 3(1):7–13CrossRef Sung J, Lim S, Kim Y, Lee J (2010) Prognostic significance of pSTAT3 and survivin expression in diffuse large B cell lymphoma. Basic and Appl Pathol 3(1):7–13CrossRef
39.
Zurück zum Zitat Paydas S, Seydaoglu G, Ergin M et al (2009) Prognostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res 33:1627–1635PubMedCrossRef Paydas S, Seydaoglu G, Ergin M et al (2009) Prognostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res 33:1627–1635PubMedCrossRef
40.
Zurück zum Zitat Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584PubMedCrossRef Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584PubMedCrossRef
41.
Zurück zum Zitat Mainou-Fowler T, Overman LM, Dignum H et al (2008) A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol 32:59–68PubMed Mainou-Fowler T, Overman LM, Dignum H et al (2008) A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol 32:59–68PubMed
42.
Zurück zum Zitat Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Deconinck E, Mougin C, Cahn JY, Fest T (2002) Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16(4):726–735PubMedCrossRef Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Deconinck E, Mougin C, Cahn JY, Fest T (2002) Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 16(4):726–735PubMedCrossRef
43.
Zurück zum Zitat Gandhi AM, Ben-Ezra JM (2004) Do Bcl-2 and survivin help distinguish benign from malignant B cell lymphoid aggregates in bone marrow biopsies? J Clin Lab Anal 18(6):285–288PubMedCrossRef Gandhi AM, Ben-Ezra JM (2004) Do Bcl-2 and survivin help distinguish benign from malignant B cell lymphoid aggregates in bone marrow biopsies? J Clin Lab Anal 18(6):285–288PubMedCrossRef
44.
Zurück zum Zitat Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M (2000) Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-1) associated lymphomas. Cancer Lett 160:89–97PubMedCrossRef Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M (2000) Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-1) associated lymphomas. Cancer Lett 160:89–97PubMedCrossRef
45.
Zurück zum Zitat Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, Caskey CT (2000) Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 97(3):1230–1235PubMedCrossRef Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, Caskey CT (2000) Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 97(3):1230–1235PubMedCrossRef
Metadaten
Titel
Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin’s lymphoma
verfasst von
Ahmed M. L. Bedewy
Maha M. Adel Elgammal
Magdy M. L. Bedewy
Shereen M. EL-Maghraby
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 10/2013
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1775-4

Weitere Artikel der Ausgabe 10/2013

Annals of Hematology 10/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.